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ABSTRACT 
 
Schizophrenia patients who are in the treatment with Typical Anti-Psychotics drugs are at higher risk of developing 
extra pyramidal symptoms. The objective of this case report is to enhance awareness for medical practioners 
concerning Typical Anti-Psychotic drugs induced Parkinsonism/Extra Pyramidal Syndrome (EPS). We report a 
patient, who is a known case of Chronic Schizophrenia, was treated with Haloperidol 5mg t.i.d for one month, this 
caused the patient to suffer with Extra Pyramidal Syndrome, and then the patient was advised to stop Haloperidol. 
Instead Atypical Anti-Psychotic Olanzapine 2.5mg orally was prescribed which showed gradual improvement and 
recovered from Extra Pyramidal syndrome after a month. 
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INTRODUCTION 
 
Schizophrenia is a psychiatric disorder, which 
manifests with multiple symptoms involving thoughts, 
perception, emotions, movements and behaviour. It is a 
major health problem which affects a sizeable 
population throughout the world [1]. It is estimated to 
affect 1% of the general population but it occurs in 
10% of people who have a first degree relative with the 
psychiatric disorders. Evidence from epidemiological 
research indicates that schizophrenia occurs in all 
populations with prevalence in the range of 1.4 to 4.6 
per 1000 and incidence rate in the range of 0.16-0.42 
per 1000 population [2]. Antipsychotic drugs have 
become the corner stone of treatment for 
schizophrenia. Approximately, 50% of patients with 
schizophrenia do not obtain adequate relief with 
conventional neuroleptics (typical antipsychotics).  
Haloperidol comes under the category of 
dopamine inverse agonist prescribed frequently for the 
treatment of schizophrenia world-wide. Though 
haloperidol is highly effective against the 
hallucinations and delusions in schizophrenia, it is not 
as useful in controlling the negative symptoms like 
extra-pyramidal side effects which results in movement 
disorders. 
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Typical antipsychotics produce extra pyramidal side 
effects e.g. acute Dystonic reactions, sub-acute 
Parkinsonism, Akathisia. Antipsychotic drug-induced 
EPS is thought to be caused by the blockage of central 
dopamine D
2 
receptors by the death of dopamine 
producing neurons [3-4]. 
Extra pyramidal symptoms are neurological 
disturbances caused by antipsychotics (or a 
neurological disorder) in the area of the brain that 
controls motor coordination. High-potency first-
generation antipsychotics, such as haloperidol and 
fluphenazine, are more likely to induce EPS than the 
low potency agents. The antipsychotics can produce 
symptoms like Parkinson-like symptoms 
(Parkinsonism) that include muscle stiffness, rigidity, 
tremor, drooling, and a “mask like” face. However, 
unlike Parkinson’s disease, which is a progressive 
neurological disease, Parkinsonism which occurred due 
to antipsychotic drugs are reversible. It may be treated 
and prevented, by using anti-parkinson drugs (also 
called anticholinergic agents), such as Benztropine, 
Diphenhydramine, Trihexyphenidyl and procyclidine 
[5]. 
Patients who are in need to take antipsychotic drugs for 
psychiatric disorder, such as those with schizophrenia 
or major depressive disorders, may be switch to 
atypical  anti-psychotics that have a lower risk of EPS 
[6] . In this case report we are going to report about the 
patient diagnosed with schizophrenia who has been on 
treatment with Typical antipsychotic (Haloperidol) for 
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1month experienced parkinsonism and further 
management was detailed below. 
CASE REPORT 
 
A thirty three old male patient was admitted with 
Parkinsonism like symptoms was under the treatment 
of Haloperidol 5mg t.i.d for the past one month, which 
was prescribed for chronic schizophrenia. He came to 
the hospital with the complaints of increased salivation, 
rigidity in movement, slowness in movement, sleep 
disturbances and slurring of speech. These symptoms 
were seen after a month when he was in haloperidolOn 
Physical examination he was found to have Cog wheel 
like rigidity and mask like face. Then the patient was 
advised to stop Haloperidol and prescribed with the 
following medicines Promethazine (Pheneragan) 1amp 
iv BD, Tetrahydropalmatine (THP) 2mg b.i.d oral, 
Olanzapine(Oleanz), Resperidone+Trihexyphenidyl 
HCL (Riswel-LS) along with Vitamin-B supplement. 
After a month gradual decrease in Extra pyramidal 
symptoms and resulted in good health outcomes. 
 
DISCUSSION 
 
Haloperidol is a typical antipsychotic drug. It comes 
under the category of dopamine inverse agonist used in 
the treatment of schizophrenia. Unfortunately, the 
therapeutic effects of Haloperidol also come with 
severe extra-pyramidal side effects, resulting in 
movement disorders. Side-effects of haloperidol 
include unusual, slowed, or uncontrolled movements of 
any part of the body, stiff or weak muscles, 
nervousness, agitation, blank facial expression, slowed 
breathing, sleepiness and  loss of consciousness.The 
Patho-physiological mechanism is associated with 
dopaminergic D2 and serotonergic 5-HT2A receptors 
blockade and low affinity of particular Anti Psychotics 
to acetylcholine receptors. Although drug-induced 
Parkinsonism is considered a reversible condition in 
most cases it usually lasts up to 4 months, it can last 6-
18 months, and in 15% of cases it has been even 
described as persistent. In case of persistent symptoms, 
antipsychotic induced Parkinson’s disease should be 
taken into consideration, and it should be treated with 
dopaminergics [3]. 
 
 CONCLUSION 
 
From this case, it was found that instead of using 
Haloperidol(First generation antipsychotics/ typical 
antipsychotics); it is good to go on with second 
generation/ atypical antipsychotics like olanzipine, 
quetiapine etc., But selection of these drugs should be 
based on the patients condition. 
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